scholarly journals Plasma sex hormone-binding globulin predicts neurodegeneration and clinical progression in prodromal Alzheimer's disease

2019 ◽  
Author(s):  
Wei Xu ◽  
Bing-Jie Su ◽  
Xue-Ning Shen ◽  
Yan-Lin Bi ◽  
Chen-Chen Tan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Brain Metabolism ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Clinical Progression ◽  
Cross Sectional ◽  
Prodromal Ad ◽  
Prodromal Alzheimer’S Disease

Abstract Background: Sex hormone-binding globulin (SHBG) in plasma has been found to be significantly elevated in subjects with AD. We aimed to investigate whether plasma SHBG was associated with AD biomarkers and could predict neurodegeneration and clinical progression in prodromal AD.Methods: The study tested the cross-sectional relationship between plasma SHBG and CSF AD biomarkers in 707 non-demented adults. Next, the longitudinal influences of plasma SHBG at baseline on dynamic changes of CSF Aβ42, hippocampus volume, brain metabolism, and cognition were explored in 448 non-demented adults from the Alzheimer’s disease Neuroimaging Initiative (ADNI). Finally, the influence of plasma SHBG on the risk of incident AD was explored. Results: This study included 707 participants (mean [SD] age, 62.5 [10.5] years, 416 [58.8%] female) from CABLE and 448 from ADNI-1 (mean [SD] age, 74.8 [7.2] years, 166 [37.5%] female). A positive correlation was found for SHBG levels in plasma and CSF (p = 2.12 × 10 -10, r = 0.44). Cross-sectional analyses indicated that individuals with higher plasma SHBG had lower levels of CSF Aβ42 (p < 0.005), after adjusting for age, gender, education, APOE4 allele, and cognitive scores. The longitudinal data showed that higher levels of plasma SHBG contribute to accelerated CSF Aβ42 decrease (p < 0.0005), brain metabolism decline (p < 0.05), hippocampus atrophy (p < 0.01), cognitive decline (p < 0.01), and higher risk of AD dementia (p < 0.05).Conclusions: Plasma SHBG is associated with CSF Aβ42 levels and could predict neurodegeneration and clinical progression in prodromal AD. This finding indicates plasma SHBG is a potentially useful, early biomarker for AD.

scholarly journals Plasma sex hormone-binding globulin predicts neurodegeneration and clinical progression in prodromal Alzheimer's disease

Aging ◽  
2020 ◽  
Vol 12 (14) ◽  
pp. 14528-14541
Author(s):  
Wei Xu ◽  
Bing-Jie Su ◽  
Xue-Ning Shen ◽  
Yan-Lin Bi ◽  
Chen-Chen Tan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Clinical Progression ◽  
Prodromal Alzheimer’S Disease

P4-044: Sex hormone binding globulin and incident Alzheimer's disease in elderly men and women

2008 ◽  
Vol 4 ◽  
pp. T681-T681
Author(s):  
Majon Muller ◽  
Nicole Schupf ◽  
Jennifer J. Manly ◽  
Richard Mayeux ◽  
José A. Luchsinger
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Elderly Men ◽  
Men And Women

Elevated sex-hormone binding globulin in elderly women with Alzheimer’s disease

2004 ◽  
Vol 25 (2) ◽  
pp. 141-147 ◽  
Author(s):  
Elena K Hoskin ◽  
Ming X Tang ◽  
Jennifer J Manly ◽  
Richard Mayeux
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Elderly Women ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding

scholarly journals Sex hormone binding globulin and incident Alzheimer’s disease in elderly men and women

2010 ◽  
Vol 31 (10) ◽  
pp. 1758-1765 ◽  
Author(s):  
Majon Muller ◽  
Nicole Schupf ◽  
Jennifer J. Manly ◽  
Richard Mayeux ◽  
José A. Luchsinger
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Elderly Men ◽  
Men And Women

scholarly journals Psychometric Properties of the Clinical Dementia Rating – Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer’s Disease Population

2020 ◽  
pp. 1-10
Author(s):  
F. McDougall ◽  
C. Edgar ◽  
M. Mertes ◽  
P. Delmar ◽  
P. Fontoura ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Psychometric Properties ◽  
Disease Assessment ◽  
Clinical Dementia Rating ◽  
Prodromal Ad ◽  
Ceiling Effects ◽  
Prodromal Alzheimer’S Disease ◽  
Selective Reminding Test

BACKGROUND: The Clinical Dementia Rating–Sum of Boxes (CDR-SB) has been proposed as a primary outcome for use in prodromal AD trials. However, the psychometric properties of this, and of other commonly used measures, have not been well-established in this patient population. OBJECTIVE: To describe the psychometric properties of commonly used efficacy measures in a clinical trial of prodromal AD. SETTING: Data were gathered as part of a two-year clinical trial. PARTICIPANTS: Patients had biomarker confirmed prodromal AD. MEASUREMENTS: Clinical Dementia Rating (CDR), Functional Activities Questionnaire (FAQ), Alzheimer’s Disease Assessment Scale – Cognition Subscale 11 and 13 (ADAS-Cog), Mini Mental State Exam (MMSE), and Free and Cued Selective Reminding Test (FCSRT-IR [words]). Assessments were conducted at least every 24 weeks. RESULTS: For the CDR-SB, test-retest reliability was good (intra-class correlation coefficient [ICC]=0.83); internal consistency was 0.65 at baseline but above 0.8 at later assessments. Relationships between the CDR-SB and other measures were as expected (higher correlations with more closely related constructs), and the CDR-SB differentiated between patients with different severities of dementia (-2.9 points difference between CDR-Global Score 0.5 and 1, P<.0001). Floor and ceiling effects on the CDR-SB total score were minimal; however, at baseline there were ceiling effects in the personal care domain. Further detail is provided on the psychometric properties of ADAS-Cog, MMSE, FCSRT-IR and FAQ in this population. CONCLUSION: The psychometric properties of the CDR-SB are adequate in prodromal AD and continued use is warranted in clinical trials. However, there remains scope for improvement in the assessment of functional constructs and development of novel measures should continue.

Development, Spanish Normative Data, and Validation of a Social Cognition Battery in Prodromal Alzheimer’s Disease and Multiple Sclerosis

2020 ◽  
Author(s):  
Alfonso Delgado-Álvarez ◽  
Vanesa Pytel ◽  
Cristina Delgado-Alonso ◽  
Carmen María Olbrich-Guzmán ◽  
Ana Cortés-Martínez ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Social Cognition ◽  
Neuropsychological Tests ◽  
Normative Data ◽  
Reactivity Index ◽  
Cognitive Domains ◽  
Prodromal Ad ◽  
Prodromal Alzheimer’S Disease

Abstract Objectives The assessment of social cognition changes may be challenging, especially in the earliest stages of some neurodegenerative diseases. Our objective was to validate a social cognition battery from a multidomain perspective. In this regard, we aimed to adapt several tests, collect normative data, and validate them in prodromal Alzheimer’s disease (AD) and multiple sclerosis (MS). Methods A total of 92 healthy controls, 25 prodromal AD, and 39 MS patients were enrolled. Age-, gender-, and education-matched control groups were created for comparisons. Social cognition battery was composed of an emotion-labeling task developed from FACES database, the Story-based Empathy test (SET), the Faux Pas test, and the Interpersonal Reactivity Index. Patients were also evaluated with a comprehensive cognitive battery to evaluate the other cognitive domains. Automatic linear modeling was used to predict each social cognition test’s performance using the neuropsychological tests examining other cognitive domains. Results The reliability of the battery was moderate-high. Significant intergroup differences were found with medium-large effect sizes. Moderate correlations were found between social cognition battery and neuropsychological tests. The emotion labeling task and SET showed moderate correlations with age and education, and age, respectively. Regression-based norms were created considering the relevant demographic variables. Linear regression models including other neuropsychological tests explained between 7.7% and 68.8% of the variance of the social cognition tests performance. Conclusions Our study provides a battery for the assessment of social cognition in prodromal AD and MS with Spanish normative data to improve the evaluation in clinical and research settings.

scholarly journals Cerebrospinal Fluid α-Synuclein Predicts Neurodegeneration and Clinical Progression in Prodromal Alzheimer's Disease

2020 ◽  
Author(s):  
Jie-Qiong Li ◽  
Yan-Lin Bi ◽  
Xue-Ning Shen ◽  
Hui-Fu Wang ◽  
Wei Xu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Characteristic Curve ◽  
Longitudinal Change ◽  
Clinical Progression ◽  
Chinese Han ◽  
Predictive Values ◽  
Potential Biomarker ◽  
Prodromal Ad

Abstract BackgroundAccumulating reports suggest that α-synuclein is involved in Alzheimer disease (AD) pathogenesis. Cerebrospinal fluid (CSF) α-synuclein could be a potential biomarker of AD. We sought to test whether CSF α-synuclein is associated with other AD biomarkers and could predict neurodegeneration and clinical progression in prodromal AD. MethodsAssociations were investigated between CSF α-synuclein and other AD biomarkers at baseline in prodromal AD stage Chinese elders. The predictive values of CSF α-synuclein in longitudinal change in clinical outcomes and conversion risk of prodromal AD stage subjects were assessed using linear mixed effects models and multivariate Cox proportional hazard models, respectively, in Alzheimer's disease Neuroimaging Initiative (ADNI) database.ResultsAmong individuals in prodromal AD stage, we detected that CSF α-synuclein levels correlated with AD-specific biomarkers CSF total tau and phosphorylated tau levels in 651 Chinese Han participants (training set). These positive correlations were replicated in ADNI database (validation set). Using a longitudinal cohort from ADNI, CSF α-synuclein concentrations increased with disease severity. CSF α-synuclein had high diagnostic accuracy for AD based on the “ATN” system (A+T+) vs controls (A-T-) (area under the receiver operating characteristic curve, 0.84). Moreover, CSF α-synuclein predicted longitudinal hippocampus atrophy and conversion from MCI to AD dementia.ConclusionsCSF α-synuclein is associated with CSF tau levels and could predict neurodegeneration and clinical progression in prodromal AD. This finding indicates CSF α-synuclein is a potentially useful, early biomarker for AD.

Cross-sectional association between testosterone, sex hormone-binding globulin and metabolic syndrome: The Healthy Twin Study

2017 ◽  
Vol 87 (5) ◽  
pp. 523-531 ◽  
Author(s):  
Heesun Moon ◽  
Inyoung Choi ◽  
Somi Kim ◽  
Hyeonyoung Ko ◽  
Jinyoung Shin ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Twin Study ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Cross Sectional
Sign in / Sign up

Export Citation Format

Share Document